Compare · ARGX vs BVXV
ARGX vs BVXV
Side-by-side comparison of argenx SE (ARGX) and BiondVax Pharmaceuticals Ltd. (BVXV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and BVXV operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $54.77B, about 1777.4x BVXV ($30.8M).
- ARGX has hit the wire 8 times in the past 4 weeks while BVXV has been quiet.
- ARGX has more recent analyst coverage (25 ratings vs 1 for BVXV).
- Company
- argenx SE
- BiondVax Pharmaceuticals Ltd.
- Price
- $891.15+1.02%
- $1.32-2.22%
- Market cap
- $54.77B
- $30.8M
- 1M return
- -8.20%
- -
- 1Y return
- +8.29%
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- 2015
- News (4w)
- 8
- 0
- Recent ratings
- 25
- 1
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
BiondVax Pharmaceuticals Ltd.
BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious diseases and related illnesses in Israel. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.
Latest ARGX
- SEC Form 6-K filed by argenx SE
- argenx Reports Third Quarter 2026 Financial Results and Provides Business Update
- argenx to Present Phase 3 ALKIVIA Results in Autoimmune Myositis as a Late-Breaking Oral Presentation at ACR Convergence 2026
- SEC Form 6-K filed by argenx SE
- argenx to Report Third Quarter 2026 Financial Results and Business Update on October 22, 2026
- SEC Form 6-K filed by argenx SE
- argenx Provides Update on Phase 3 UNITY Study of Efgartigimod SC in Sjögren's Disease
- argenx Announces Positive Topline Results from Phase 2 Study of FB102 in Celiac Disease
- SEC Form 6-K filed by argenx SE
- argenx Presents New Data at AANEM and MGFA Scientific Session Showcasing Earlier and Sustained Treatment in MG and CIDP with VYVGART and Progress Across its Neuromuscular Pipeline
Latest BVXV
- SEC Form SC 13G filed by BiondVax Pharmaceuticals Ltd.
- SEC Form EFFECT filed by BiondVax Pharmaceuticals Ltd.
- SEC Form F-3 filed by BiondVax Pharmaceuticals Ltd.
- SEC Form SC 13G/A filed by BiondVax Pharmaceuticals Ltd. (Amendment)
- SEC Form 6-K filed by BiondVax Pharmaceuticals Ltd.
- SEC Form D filed by BiondVax Pharmaceuticals Ltd.
- SEC Form 6-K filed by BiondVax Pharmaceuticals Ltd.
- SEC Form 6-K filed by BiondVax Pharmaceuticals Ltd.
- SEC Form SC 13G/A filed by BiondVax Pharmaceuticals Ltd. (Amendment)
- SEC Form 424B3 filed by BiondVax Pharmaceuticals Ltd.